DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/61183d/womens_health_the) has announced the addition of the "Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/41867b/cancer_drug_resist) has announced the addition of the "Cancer Drug Resistance" report to their offering. Drug resistance is the single most important cause of cancer treatment (…)
[Read article]
[Source: Business Wire]
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees. The restricted stock unit awards vest as to 1/4th of the (…)
[Read article]
[Source: Business Wire]
LOS ANGELES-(BUSINESS WIRE)-ImmunoCellular Therapeutics (OTCBB: IMUC) issued the following Letter to Shareholders today: Dear Shareholders, As the summer comes to a close, I wanted to update you on the Company s accomplishments this year, which set the stage for an exciting (…)
[Read article]
[Source: Business Wire]
ZURICH/BASEL, Sept 3 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) will review its business and cut costs to cope with recent setbacks on key drugs and rising pressures on prices from healthcare reforms, it said on Friday.
[Read article]
[Source: BioSpace]
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing (…)
[Read article]
[Source: Medical News Today]
Siemens Healthcare Diagnostics announces Eric Olson's appointment as President of the IVD Industry Connectivity Consortium (IICC). Founded by the top worldwide in vitro diagnostics (IVD) manufacturers, IICC's mission is to create and ensure adoption of a unified connectivity (…)
[Read article]
[Source: Medical News Today]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each (…)
[Read article]
[Source: Business Wire]
ROCKVILLE, Md.-(BUSINESS WIRE)-RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) ( the Company or RegeneRx ) today announced that R. Don Elsey has been appointed to the Company s board of directors, effective September 1. Mr. Elsey will serve on the compensation and (…)
[Read article]
[Source: Business Wire]
02 September 2010 - The new Illumina HiSeq 2000 is added to LGC Genomics next generation sequencing portfolio LGC Genomics, the genomics division of LGC, announces the acquisition of the latest next generation sequencing technology Illumina HiSeq 2000 to its sequencing (…)
[Read article]
[Source: BioSpace]
GENEVA, SWITZERLAND-(Marketwire - September 02, 2010) - Addex Pharmaceuticals / Addex drug-candidate effective in Alzheimer's disease model processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Allosteric modulation (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Argentina Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
TUCSON, Ariz.-(BUSINESS WIRE)-HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA ¢), today announced the appointments of John Wineman as Vice President New Business Development, Western Region and Thomas Vasicek, Ph.D., as Vice President Clinical (…)
[Read article]
[Source: Business Wire]
MONTREAL, CANADA-(Marketwire - September 01, 2010) - Theratechnologies (TSX: TH) announced today the appointment of Mr. John-Michel T. Huss as President and Chief Executive Officer of the Company. Mr. Huss will assume his responsibilities in the coming months. Until recently, (…)
[Read article]
[Source: BioSpace]
LEUVEN, Belgium, September 1, 2010 /PRNewswire-FirstCall/ - - Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin's Potential to Transform the Treatment of Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused (…)
[Read article]
[Source: BioSpace]
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, announced that Genentech, a member of the Roche Group, announced its receipt of a Refuse to File (RTF) letter from the US Food and Drug Administration (FDA) for (…)
[Read article]
[Source: Medical News Today]
For competitive bicyclists with goals - whether competing in the Tour de France or aiming for the podium at a local race - faster cycling comes from training regimens based on various zones of exercise intensity. New research from exercise scientists at the University of New (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6feb42/biotechnology_in_c) has announced the addition of the "Biotechnology in China" report to their offering. The Biotechnology in China industry profile is an essential resource for (…)
[Read article]
[Source: Business Wire]
PARIS-(BUSINESS WIRE)-Regulatory News: Above and beyond the transaction with Inspiration and its diversified international presence, the Group continues to secure its future by actively developing its rich R&D pipeline. The Board of Directors of Ipsen (Paris:IPN) (Euronext: (…)
[Read article]
[Source: Business Wire]
August 31, 2010 - Roche Holding AG is planning to make massive job cuts soon, according to newspaper reports, involving more than several hundreds of employees around the world including positions in sales, R&D, production and administration. The reduction in (…)
[Read article]
[Source: BioSpace]
ScienceDaily (Aug. 30, 2010) For competitive bicyclists with goals whether competing in the Tour de France or aiming for the podium at a local race faster cycling comes from training regimens based on various zones of exercise intensity. New research from exercise scientists at (…)
[Read article]
[Source: ScienceDaily]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Dermatology research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)
[Read article]
[Source: Business Wire]
Beltsville, MD, August 30, 2010 - BioServe today launched The BioServe Network (BSN), a network of leading academic, medical, and industry biosample repositories that creates the largest resource of high-quality biosamples for the life science industry. The charter members of (…)
[Read article]
[Source: BioSpace]
The Food and Drug Administration (FDA) has issued a Refuse to File letter for accelerated approval of Roche's trastuzumab-DM1 (T-DM1) Biologics License Application, which was submitted in July 2010. Roche had requested accelerated approval for T-DM1 based on the results of a (…)
[Read article]
[Source: Medical News Today]
Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients, according to a study appearing in an upcoming issue of the Journal of the (…)
[Read article]
[Source: Medical News Today]
Transforming the U.S. health care system from paper-based to electronic-based may improve health care quality and reduce costs, but a new study by researchers from the Harvard School of Public Health (HSPH) suggests that goal is far off. The adoption of basic or comprehensive (…)
[Read article]
[Source: Medical News Today]
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company s trastuzumab-DM1 (T-DM1) (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/910f92/epigenetics_tools) has announced the addition of the "Epigenetics: Tools, Diagnostics, Drugs and World Market" report to their offering. Epigenetics: Tools, Diagnostics, Drugs and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)
[Read article]
[Source: Business Wire]
Context: Glucokinase plays a key role in glucose homeostasis. Glucokinase activators can lower glucose levels in both animal and human type 2 diabetes, but their mechanism of action has never been explored in humans. Objective: The objective of the study was to investigate the (…)
[Read article]
[Source: NCBI PubMed]
The purpose of this study was to evaluate the in vivo dose-response relation of chromosome aberration formation and distribution in a context of localised and fractionated radiotherapy. Cytogenetic analysis was applied to eight patients, all treated for the same tumour (…)
[Read article]
[Source: NCBI PubMed]
Objectives: Dalcetrapib, which targets cholesteryl ester transfer protein, is in clinical development for prevention of cardiovascular events and is likely to be used concomitantly with statins. Two studies investigated co-administration of dalcetrapib with atorvastatin and any (…)
[Read article]
[Source: NCBI PubMed]
OBJECTIVE.: To evaluate changes in vascular and musculoskeletal involvement in subjects in the Scleroderma Lung Study (SLS), a multicenter, double-blind, randomized, controlled trial comparing placebo treatment to oral cyclophosphamide for 1 year in systemic sclerosis (SSc) (…)
[Read article]
[Source: NCBI PubMed]
ABSTRACT: BACKGROUND: Diatoms represent the predominant group of eukaryotic phytoplankton in the oceans and are responsible for around 20% of global photosynthesis. Two whole genome sequences are now available. Notwithstanding, our knowledge of diatom biology remains limited (…)
[Read article]
[Source: NCBI PubMed]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN - News), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Genentech, a member of the Roche Group, today announced its receipt of a Refuse to File (RTF) letter (…)
[Read article]
[Source: BioSpace]
Leuven, Belgium 26 August, 2010 ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, is today issuing a business update in conjunction with (…)
[Read article]
[Source: BioSpace]
ScienceDaily (Aug. 26, 2010) Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein (…)
[Read article]
[Source: ScienceDaily]
ScienceDaily (Aug. 26, 2010) Transforming the U.S. health care system from paper-based to electronic-based may improve health care quality and reduce costs, but a new study by researchers from the Harvard School of Public Health (HSPH) suggests that goal is far off. The (…)
[Read article]
[Source: ScienceDaily]
A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Center and colleagues at (…)
[Read article]
[Source: Medical News Today]
Ambry Genetics, a global leader in genomic services, announced that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. Ambry Genetics has been an early adapter of (…)
[Read article]
[Source: Medical News Today]
A phase 1 clinical trial using a new formulation of an experimental drug that targets the BRAF cancer gene, has shown early promise in treating melanoma in patients with a mutated form of the gene and whose skin cancer has progressed to the metastatic stage. A paper on the (…)
[Read article]
[Source: Medical News Today]
USA Today recently published an editorial and an opinion piece regarding the recent controversy surrounding the cancer drug Avastin. An FDA advisory panel in July voted 12-1 to recommend that the agency revoke Avastin's approval to treat advanced breast cancer after two (…)
[Read article]
[Source: Medical News Today]